Epix nears Australia approval for Vasovist

MRI contrast developer Epix Pharmaceuticals said that the Australian Drug Evaluation Committee (ADEC) has recommended the firm's Vasovist blood pool imaging agent for approval in Australia.

Approval is subject to the finalization of labeling, according to the Cambridge, MA-based company.

By AuntMinnie.com staff writers
August 14, 2006

Related Reading

Epix grows revenues in Q2, August 7, 2006

FDA extends Epix's Vasovist appeal, July 31, 2006

Epix retains rights to EP-2104R, July 13, 2006

Epix files Vasovist appeal with FDA, July 4, 2006

Astrue resigns from Epix, May 8, 2006

Copyright © 2006 AuntMinnie.com

Page 1 of 606
Next Page